The researchers found that 6.5% of adults experienced cost burdens and 3.5% had CCBs during year one; 17.4% and 9.9%, respectively, experienced these outcomes at least once over 4 years. Overall, 24.7 ...
Setrusumab is a monoclonal antibody that inhibits sclerostin, a protein that negatively regulates bone development, allowing for new bone formation.
Receipt of educational leaflet also reduces misperception of asymptomatic bacteriuria as urinary tract infection.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback